Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm plus NSCLC and Acquired T790M: The Real-World UpSwinG study

被引：0
|
作者：
Popat, S. [1 ,2 ]
Jung, H. A. [3 ]
Lee, S. Y. [4 ]
Hochmair, M. J. [5 ]
Lee, S. H. [6 ]
Escriu, C. [7 ]
Lee, M. K. [8 ]
Migliorino, M. R. [9 ]
Lee, Y. C. [10 ]
Girard, N. [11 ]
Daoud, H. [12 ]
Marten, A. [12 ]
Miura, S. [13 ]
机构：
[1] Royal Marsden Natl Hlth Serv Fdn Trust, Lung Unit, London, England
[2] Inst Canc Res, London, England
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[4] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
[5] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria
[6] Kyung Hee Univ, Div Pulm & Crit Care Med, Dept Internal Med, Med Ctr,Sch Med, Seoul, South Korea
[7] Clatterbridge Canc Ctr, Wirral, Merseyside, England
[8] Pusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea
[9] San Camillo Forlanini Hosp, Rome, Italy
[10] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Biomed Res Inst,Dept Internal Med,Med Sch, Jeonju, South Korea
[11] Inst Thorax Curie Montsouris, Inst Curie, Thorac Surg, Paris, France
[12] Boehringer Ingelheim Int Gmbh, Ingelheim, Germany
[13] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
EGFR mutation-positive NSCLC; osimertinib; afatinib;
D O I：
10.1016/j.jtho.2021.08.542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P51.05
引用
收藏
页码：S1120 / S1121
页数：2
相关论文
共 50 条
  • [1] Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
    Popat, Sanjay
    Jung, Hyun Ae
    Lee, Shin Yup
    Hochmair, Maximilian J.
    Lee, Seung Hyeun
    Escriu, Carles
    Lee, Min Ki
    Migliorino, Maria R.
    Lee, Yong Chul
    Girard, Nicolas
    Daoud, Hasan
    Marten, Angela
    Miura, Satoru
    [J]. LUNG CANCER, 2021, 162 : 9 - 15
  • [2] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)
    Popat, S.
    Jung, H. A.
    Lee, S. Yup
    Hochmair, M. J.
    Lee, S. H.
    Escriu, C.
    Lee, M. K.
    Migliorino, M. R.
    Lee, Y. C.
    Girard, N.
    Daoud, H.
    Maerten, A.
    Miura, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S971 - S972
  • [3] Intracranial Activity of Osimertinib in Naive EGFRm T790M(-) And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
    Peled, N.
    Nechushtan, H.
    Ilouze, M.
    Dudnik, E.
    Inbar, E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2223 - S2223
  • [4] Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm plus ) NSCLC: Final analysis of Asian patients in the GioTag study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R. A.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Marten, A.
    Cufer, T.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1399 - S1399
  • [5] UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
    Miura, S.
    Maerten, A.
    Popat, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1405 - S1406
  • [6] Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan
    Chang, G.
    Shih, J.
    Chao, H.
    Yang, C.
    Lin, C.
    Hung, J.
    Hsiao, S.
    Wang, C.
    Chian, C.
    Hsia, T.
    Yu, C.
    Chen, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S679 - S679
  • [7] Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)
    Cheema, P.
    Passaro, A.
    Martin, C.
    Tiseo, M.
    Park, K.
    Chang, G.
    Hu, Y.
    Cho, B. C.
    Miranda, M.
    Fernandes, A.
    Freitas, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S854 - S854
  • [8] START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm plus Advanced NSCLC
    Zhou, J.
    Xue, Z.
    Li, Q.
    Ling, X.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S632 - S633
  • [9] ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis
    Kim, S.
    Cho, B. C.
    Kim, D.
    Park, K.
    Tiseo, M.
    Migliorino, M. R.
    Santo, A.
    Lee, J.
    Vicente, D.
    Paredes, A.
    O'Hanrahan, E.
    Freitas, H.
    Provencio, M.
    Chen, Y.
    Cheema, P.
    Milner, A.
    Rigas, J.
    Wu, Y.
    De Marinis, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2202 - S2202
  • [10] Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
12345